for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cue Biopharma Inc

CUE.OQ

Latest Trade

--

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

--

 - 

--

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
--
Open
--
Volume
--
3M AVG Volume
2.72
Today's High
--
Today's Low
--
52 Week High
--
52 Week Low
--
Shares Out (MIL)
22.99
Market Cap (MIL)
268.80
Forward P/E
-6.80
Dividend (Yield %)
--

Latest Developments

More

Cue Biopharma Reports Third Quarter 2019 Financial Results

Cue Biopharma Qtrly Loss Per Share $0.31

Cue Biopharma Promotes Dr. Anish Suri To President And CSO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cue Biopharma Inc

Cue Biopharma Inc is a development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework, and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program, and MHC Class II Program. The CUE-100 Framework restricts the activity of T cell populations. The CUE-200 Framework enables potent, long-lived anti-tumor T cell responses. The Autoimmune disease therapy protects the healthy cells from immune attack.

Industry

Biotechnology & Drugs

Contact Info

21 Erie St

+1.617.9492680

https://www.cuebiopharma.com/

Executive Leadership

Barry J. Simon

Independent Chairman of the Board

Anish Suri

President, Chief Scientific Officer

Daniel R. Passeri

Chief Executive Officer, Director

Rodolfo J. Chaparro

Executive Vice President - Head of Immunology

Ronald D. Seidel

Executive Vice President - Head of Research and Development

Key Stats

1.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-1.940

2019(E)

-1.720
Price To Earnings (TTM)
--
Price To Sales (TTM)
98.12
Price To Book (MRQ)
9.94
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-106.17
Return on Equity (TTM)
-87.76

Latest News

Latest News

BRIEF-Peter Appel Reports Passive Stake Of 7.6 Pct In Cue Biopharma

* PETER APPEL REPORTS A PASSIVE STAKE OF 7.6 PERCENT IN CUE BIOPHARMA INC AS OF DEC 27, 2017 - SEC FILING Source text: (http://bit.ly/2BWquxU) Further company coverage:

BRIEF-Mark Strome Reports 5.7 Pct Passive Stake In Cue Biopharma

* MARK STROME REPORTS A 5.7 PERCENT PASSIVE STAKE IN CUE BIOPHARMA INC AS OF DECEMBER 27, 2017- SEC FILING Source: (http://bit.ly/2AIDG48) Further company coverage:

BRIEF-Cue Biopharma sees IPO of up to 8 mln shares of its common stock priced at $7.50/shr

* CUE BIOPHARMA INC SEES IPO OF UP TO 8 MILLION SHARES OF ITS COMMON STOCK PRICED AT $7.50 PER SHARE - SEC FILING

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up